Simplifying Global Compliance

Recommended Products

Gmp-inspection-preparation-checklist-130x160

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.

Biological-risk-eval-and-mngmnt-for-md-130x160

Biological Risk Evaluation and Management for Medical Devices

Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.

Editor's Picks

View all

Alliance Precision Plastics Cited for Lack of Written Procedures

The firm’s procedure for customer complaints did not gather enough detail to ensure they were processed in a uniform manner.

Gavelwithbasebw

Judge Dismisses Drug Kickback Lawsuit Against Eli Lilly, Allows for Repleading

The judge found that the group’s claims were not strong enough, as it did not “set forth facts alleging an agreement to conspire.”

Home » BIOMIRA REPORTS LUNG CANCER DRUG STUDY RESULTS

BIOMIRA REPORTS LUNG CANCER DRUG STUDY RESULTS

Biomira has reported results from a clinical trial of its non-small cell lung cancer drug, Stimuvax.

The final survival results from an analysis of the Phase IIb data confirmed a median survival in patients with Stage IIIB cancer of 30.6 months with Stimuvax, while patients in the same stage who were in a control test group had a median survival of 13.3 months.

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 – Fax (703) 538-7676 – Toll free (888) 838-5578.

Copyright ©2018. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing